AR114941A1 - Derivados de sulfonilurea - Google Patents
Derivados de sulfonilureaInfo
- Publication number
- AR114941A1 AR114941A1 ARP180103694A ARP180103694A AR114941A1 AR 114941 A1 AR114941 A1 AR 114941A1 AR P180103694 A ARP180103694 A AR P180103694A AR P180103694 A ARP180103694 A AR P180103694A AR 114941 A1 AR114941 A1 AR 114941A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- halo
- optionally substituted
- cycloalkyl
- haloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/66—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Abstract
La presente descripción se refiere a compuestos de la fórmula (1), y a sus sales farmacéuticamente aceptables, composiciones farmacéuticas, métodos de uso y métodos para su preparación. Los compuestos revelados en la presente son de utilidad para inhibir la maduración de las citoquinas de la familia IL-1 por inhibición de inflamasomas y se pueden usar en el tratamiento de trastornos en los que está implicada la actividad de inflamasomas, tales como enfermedades inflamatorias, autoinflamatorias y autoinmunes y cánceres. Reivindicación 1: Un compuesto de la fórmula (1), o uno de sus profármacos, solvatos o sales farmacéuticamente aceptables, en donde: R¹ es cicloalquilo C₃₋₁₆ o arilo C₅₋₁₀, en donde el cicloalquilo C₃₋₈ monocíclico, cicloalquilo policíclico o arilo C₅₋₆ está opcionalmente sustituido con uno o más R¹S; en donde cada R¹S es, de modo independiente, alquilo C₁₋₆, haloalquilo C₁₋₆, alcoxi C₁₋₆, haloalcoxi C₁₋₆ o halo; R² es -(CX²X²)ₙ-R²S, en donde n es 0, 1 ó 2 y cada X² es, de modo independiente, H, alquilo C₁₋₆, alquenilo C₂₋₆ o alquinilo C₂₋₆, en donde el alquilo C₁₋₆, alquenilo C₂₋₆ o alquinilo C₂₋₆ está opcionalmente sustituido con uno o más halo, -CN, -OH, -O(alquilo C₁₋₆), -NH₂, -NH(alquilo C₁₋₆), -N(alquilo C₁₋₆)₂ u oxo; R²S es heterocicloalquilo de 4 a 8 miembros opcionalmente sustituido con uno o más alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, haloalquilo C₁₋₆, halo, -CN, -OH, -O(alquilo C₁₋₆), -NH₂, -NH(alquilo C₁₋₆), -N(alquilo C₁₋₆)₂ u oxo; y R³ es heterocicloalquilo de 7 a 12 miembros o heteroarilo de 5 ó 6 miembros opcionalmente sustituido con uno o más R³S, en donde cada R³S es, de modo independiente, alquilo C₁₋₆, haloalquilo C₁₋₆, cicloalquilo C₃₋₈, halo o heterocicloalquilo C₃₋₈, en donde el alquilo C₁₋₆, haloalquilo C₁₋₆, cicloalquilo C₃₋₈ o heterocicloalquilo C₃₋₈ está opcionalmente sustituido con -O(alquilo C₁₋₆), -N(alquilo C₁₋₆)₂, halo o -CN.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1721185.5A GB201721185D0 (en) | 2017-12-18 | 2017-12-18 | Sulphonyl urea derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
AR114941A1 true AR114941A1 (es) | 2020-11-11 |
Family
ID=61008658
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP180103694A AR114941A1 (es) | 2017-12-18 | 2018-12-18 | Derivados de sulfonilurea |
Country Status (17)
Country | Link |
---|---|
US (2) | US11518757B2 (es) |
EP (1) | EP3728238A1 (es) |
JP (1) | JP7339959B2 (es) |
KR (1) | KR20200101423A (es) |
CN (1) | CN111954670A (es) |
AR (1) | AR114941A1 (es) |
AU (1) | AU2018391675B2 (es) |
BR (1) | BR112020011779A2 (es) |
CA (1) | CA3084694A1 (es) |
EA (1) | EA202091512A1 (es) |
GB (1) | GB201721185D0 (es) |
IL (1) | IL275058A (es) |
MX (1) | MX2020006399A (es) |
SG (1) | SG11202005081QA (es) |
TW (1) | TWI813610B (es) |
WO (1) | WO2019121691A1 (es) |
ZA (1) | ZA202003409B (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3047336A1 (en) | 2017-01-23 | 2018-07-26 | Jecure Therapeutics, Inc. | Chemical compounds as inhibitors of interleukin-1 activity |
GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
PE20211049A1 (es) | 2018-07-20 | 2021-06-04 | Hoffmann La Roche | Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1 |
AU2019322546A1 (en) * | 2018-08-15 | 2021-03-04 | Inflazome Limited | Novel sulfonamideurea compounds |
US20230083495A1 (en) * | 2019-06-12 | 2023-03-16 | NodThera Limited | Sulfonylurea derivatives and uses thereof |
EP3983387B1 (en) * | 2019-06-12 | 2024-04-24 | Nodthera Limited | Sulfonylurea derivatives and uses thereof |
EP3983388A1 (en) * | 2019-06-12 | 2022-04-20 | Nodthera Limited | Sulfonamide derivatives and uses thereof |
WO2021188450A1 (en) | 2020-03-16 | 2021-09-23 | Zomagen Biosciences Ltd | Nlrp3 modulators |
EP4135843A1 (en) | 2020-04-15 | 2023-02-22 | JANSSEN Pharmaceutica NV | Pyrazolo[1,5-d][1,2,4]triazine-5(4h)-acetamides as inhibitors of the nlrp3 inflammasome pathway |
JP2023521242A (ja) | 2020-04-15 | 2023-05-23 | ヤンセン ファーマシューティカ エヌ.ベー. | NLRP3インフラマソーム経路の阻害剤としてのピロロ[1,2-d][1,2,4]トリアジン-2-イル-アセトアミド |
US20230203064A1 (en) | 2020-04-23 | 2023-06-29 | Janssen Pharmaceutica Nv | Tricyclic compounds as inhibitors of nlrp3 |
US20230183249A1 (en) | 2020-04-30 | 2023-06-15 | Janssen Pharmaceutica Nv | New triazinoindole compounds |
AU2021279305A1 (en) | 2020-05-28 | 2023-02-09 | Janssen Pharmaceutica Nv | Compounds |
CN115768749B (zh) | 2020-06-11 | 2024-04-19 | 辰欣药业股份有限公司 | 二甲基亚磺酰亚胺衍生物 |
JP2023540733A (ja) * | 2020-09-04 | 2023-09-26 | ノッドセラ リミテッド | アルキルオキサシクロアルキル部分を含むスルファモイル尿素誘導体およびその使用 |
CN112079729A (zh) * | 2020-09-22 | 2020-12-15 | 海南梵圣生物科技有限公司 | 一种3-烷基-5-三氟甲基苯胺的制备方法 |
EP3974415A1 (en) | 2020-09-24 | 2022-03-30 | Janssen Pharmaceutica NV | Nlrp3 modulators |
CN116194445A (zh) | 2020-09-24 | 2023-05-30 | 詹森药业有限公司 | 新化合物 |
WO2022187804A1 (en) * | 2021-03-02 | 2022-09-09 | Icahn School Of Medicine At Mount Sinai | Benzoxazolone inhibitors of inflammasomes |
BR112023017434A2 (pt) | 2021-03-04 | 2023-09-26 | Janssen Pharmaceutica Nv | Derivados de 4-alcóxi-6-oxo-piridazina que modulam nlrp3 |
CA3208414A1 (en) | 2021-03-04 | 2022-09-09 | Daniel Oehlrich | 4-amino-6-oxo-pyridazine derivatives modulating nlrp3 |
WO2022229315A1 (en) | 2021-04-29 | 2022-11-03 | Janssen Pharmaceutica Nv | Phthalazinone derivatives as nlrp3 inflammasome inhibitors |
KR20240029027A (ko) | 2021-07-01 | 2024-03-05 | 얀센 파마슈티카 엔브이 | 5-옥소-피리도[2,3-d]피리다진-6(5H)-일 아세트아미드 |
WO2024064245A1 (en) | 2022-09-23 | 2024-03-28 | Merck Sharp & Dohme Llc | Phthalazine derivatives useful as inhibitors of nod-like receptor protein 3 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5214206A (en) | 1990-11-07 | 1993-05-25 | Warner-Lambert Company | Aminosulfonyl urea acat inhibitors |
DE4217719A1 (de) | 1992-05-29 | 1993-12-02 | Bayer Ag | Zweifach heterocyclisch substituierte Sulfonylamino(thio)carbonylverbindungen |
JP3355237B2 (ja) | 1993-10-15 | 2002-12-09 | 呉羽化学工業株式会社 | N−(置換アミノ)ピロール誘導体、その製造方法及び除草剤 |
US6028201A (en) | 1996-01-30 | 2000-02-22 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
WO1998032733A1 (en) * | 1997-01-29 | 1998-07-30 | Pfizer Inc. | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity |
JP4556371B2 (ja) | 1999-09-30 | 2010-10-06 | 三菱化学株式会社 | アシルスルホンアミド誘導体 |
US6593356B2 (en) | 1999-10-20 | 2003-07-15 | Bristol-Myers Squibb Pharma Company | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents |
EP1281399A3 (en) | 2001-08-01 | 2004-02-11 | Warner-Lambert Company | Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production |
US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
US7279576B2 (en) | 2002-12-31 | 2007-10-09 | Deciphera Pharmaceuticals, Llc | Anti-cancer medicaments |
US20070191336A1 (en) | 2003-12-24 | 2007-08-16 | Flynn Daniel L | Anti-inflammatory medicaments |
AU2005325676A1 (en) | 2004-12-23 | 2006-08-03 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
US9271969B2 (en) | 2012-02-07 | 2016-03-01 | Kainos Medicine, Inc. | Compounds as inhibitors of diacylglycerol O-acyltransferase type 1 enzyme |
US9410217B2 (en) | 2014-02-18 | 2016-08-09 | Renmatix, Inc. | Method of reducing a fermentation and/or enzyme inhibitor in a saccharide-containing composition |
EP3578547B1 (en) | 2015-02-16 | 2021-05-26 | The University of Queensland | Sulfonylureas and related compounds and use of same |
SG11201806745RA (en) * | 2016-02-16 | 2018-09-27 | Univ Queensland | Sulfonylureas and related compounds and use of same |
US10080742B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
WO2017189663A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
US10080741B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
US10144729B2 (en) | 2016-05-18 | 2018-12-04 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
WO2017201155A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF |
WO2017201152A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
EP3272739A1 (en) | 2016-07-20 | 2018-01-24 | NodThera Limited | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity |
MX2020001778A (es) | 2017-08-15 | 2020-03-24 | Inflazome Ltd | Nuevos compuestos de sulfonamida carboxamida. |
EP3668862A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
US20200361895A1 (en) | 2017-08-15 | 2020-11-19 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
JP2020531453A (ja) | 2017-08-15 | 2020-11-05 | インフレイゾーム リミテッド | Nlrp3阻害剤としてのスルホニルウレアおよびスルホニルチオウレア |
EP3668840A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
WO2019034693A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
UY37848A (es) | 2017-08-15 | 2019-03-29 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 |
GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
AU2019322546A1 (en) | 2018-08-15 | 2021-03-04 | Inflazome Limited | Novel sulfonamideurea compounds |
GB201902327D0 (en) | 2019-02-20 | 2019-04-03 | Inflazome Ltd | Novel compounds |
US20230083495A1 (en) | 2019-06-12 | 2023-03-16 | NodThera Limited | Sulfonylurea derivatives and uses thereof |
EP3983387B1 (en) | 2019-06-12 | 2024-04-24 | Nodthera Limited | Sulfonylurea derivatives and uses thereof |
-
2017
- 2017-12-18 GB GBGB1721185.5A patent/GB201721185D0/en not_active Ceased
-
2018
- 2018-12-18 JP JP2020552142A patent/JP7339959B2/ja active Active
- 2018-12-18 TW TW107145778A patent/TWI813610B/zh active
- 2018-12-18 WO PCT/EP2018/085511 patent/WO2019121691A1/en unknown
- 2018-12-18 AU AU2018391675A patent/AU2018391675B2/en active Active
- 2018-12-18 US US16/955,284 patent/US11518757B2/en active Active
- 2018-12-18 EP EP18826609.2A patent/EP3728238A1/en active Pending
- 2018-12-18 SG SG11202005081QA patent/SG11202005081QA/en unknown
- 2018-12-18 CA CA3084694A patent/CA3084694A1/en active Pending
- 2018-12-18 MX MX2020006399A patent/MX2020006399A/es unknown
- 2018-12-18 BR BR112020011779-0A patent/BR112020011779A2/pt unknown
- 2018-12-18 KR KR1020207020949A patent/KR20200101423A/ko not_active Application Discontinuation
- 2018-12-18 AR ARP180103694A patent/AR114941A1/es unknown
- 2018-12-18 CN CN201880089611.4A patent/CN111954670A/zh active Pending
- 2018-12-18 EA EA202091512A patent/EA202091512A1/ru unknown
-
2020
- 2020-06-02 IL IL275058A patent/IL275058A/en unknown
- 2020-06-08 ZA ZA2020/03409A patent/ZA202003409B/en unknown
-
2022
- 2022-10-17 US US17/967,599 patent/US20230145050A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
SG11202005081QA (en) | 2020-06-29 |
BR112020011779A2 (pt) | 2020-11-17 |
KR20200101423A (ko) | 2020-08-27 |
US20230145050A1 (en) | 2023-05-11 |
JP2021506966A (ja) | 2021-02-22 |
JP7339959B2 (ja) | 2023-09-06 |
CN111954670A (zh) | 2020-11-17 |
TWI813610B (zh) | 2023-09-01 |
IL275058A (en) | 2020-07-30 |
CA3084694A1 (en) | 2019-06-27 |
US11518757B2 (en) | 2022-12-06 |
TW201930291A (zh) | 2019-08-01 |
AU2018391675A1 (en) | 2020-06-18 |
EA202091512A1 (ru) | 2020-11-10 |
ZA202003409B (en) | 2022-11-30 |
WO2019121691A1 (en) | 2019-06-27 |
MX2020006399A (es) | 2020-09-07 |
US20210002261A1 (en) | 2021-01-07 |
AU2018391675B2 (en) | 2024-02-01 |
EP3728238A1 (en) | 2020-10-28 |
GB201721185D0 (en) | 2018-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR114941A1 (es) | Derivados de sulfonilurea | |
UY37848A (es) | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 | |
AR109596A1 (es) | Compuestos pirazolopiridina y sus usos | |
AR119698A2 (es) | Compuesto amida n-urea sustituida derivado de aminoácido | |
AR113909A1 (es) | Compuestos y sus composiciones farmacéuticas para el tratamiento de hepatitis b | |
AR086983A1 (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
AR109348A1 (es) | Sulfonilureas y compuestos relacionados y sus usos | |
AR087760A1 (es) | Heterociclilaminas como inhibidores de pi3k | |
HRP20210775T1 (hr) | Predlijekovi fenolnih agonista trpv1 | |
AR110782A1 (es) | Derivados de tirosinamida como inhibidores de rho-quinasa | |
CU20160097A7 (es) | Compuestos de imidazopirazina como inhibidores de syk | |
AR094964A1 (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRASTORNOS RELACIONADOS CON LA FOSFOINOSITIDA 3-CINASA d (PI3Kd) | |
AR095426A1 (es) | Inhibidores tripeptídicos de la epoxicetona proteasa | |
AR100714A1 (es) | Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaespiro undecano que tienen actividad multimodal contra el dolor | |
AR106070A1 (es) | Benzamidas sustituidas con isoxazolina como insecticidas | |
AR067060A1 (es) | Derivados de guanina policiclicos y sus metodos de uso | |
AR100713A1 (es) | Derivados de amida de compuestos de 1-oxa-4,9-diazaespiro undeceno que tienen actividad multimodal contra el dolor | |
AR100715A1 (es) | Derivados de alquilo de compuestos 1-oxa-4,9-diazaespiro undeceno que tienen actividad multimodal contra el dolor | |
PE20191103A1 (es) | Inhibidores de dopamina-b-hidroxilasa | |
AR093128A1 (es) | Inhibidores de la syk | |
AR106185A1 (es) | Compuestos macrocíclicos de sulfondiimina | |
AR113947A1 (es) | Derivados de azaindol como inhibidores de rho-quinasa | |
AR086865A1 (es) | Metodos y composiciones para el tratamiento del cancer de cerebro | |
AR085817A1 (es) | Derivados de isoxazolidina | |
AR109467A1 (es) | Compuestos, procedimiento de obtención de los compuestos, composición farmacéutica, uso de los compuestos y método de tratamiento de desórdenes psiquiátricos y/o trastornos del sueño |